BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25579888)

  • 1. Reconstitution of natural killer cells in HLA-matched HSCT after reduced-intensity conditioning: impact on clinical outcome.
    Pical-Izard C; Crocchiolo R; Granjeaud S; Kochbati E; Just-Landi S; Chabannon C; Frassati C; Picard C; Blaise D; Olive D; Fauriat C
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):429-39. PubMed ID: 25579888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Société Française de Greffe de Moelle Osseuse et Thérapie Cellulaire and Eurocord.
    Nguyen S; Achour A; Souchet L; Vigouroux S; Chevallier P; Furst S; Sirvent A; Bay JO; Socié G; Ceballos P; Huynh A; Cornillon J; Francois S; Legrand F; Yakoub-Agha I; Michel G; Maillard N; Margueritte G; Maury S; Uzunov M; Bulabois CE; Michallet M; Clement L; Dauriac C; Bilger K; Lejeune J; Béziat V; Rocha V; Rio B; Chevret S; Vieillard V
    Bone Marrow Transplant; 2017 Oct; 52(10):1428-1435. PubMed ID: 28650455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab.
    Willemsen L; Jol-van der Zijde CM; Admiraal R; Putter H; Jansen-Hoogendijk AM; Ostaijen-Ten Dam MM; Wijnen JT; van Kesteren C; Waaijer JL; Lankester AC; Bredius RG; van Tol MJ
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):473-82. PubMed ID: 25485863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
    Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
    Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.
    Nowak J; Kościńska K; Mika-Witkowska R; Rogatko-Koroś M; Mizia S; Jaskuła E; Polak M; Mordak-Domagała M; Lange J; Gronkowska A; Jędrzejczak WW; Kyrcz-Krzemień S; Markiewicz M; Dzierżak-Mietła M; Tomaszewska A; Nasiłowska-Adamska B; Szczepiński A; Hałaburda K; Hellmann A; Czyż A; Gil L; Komarnicki M; Wachowiak J; Barańska M; Kowalczyk J; Drabko K; Goździk J; Wysoczańska B; Bogunia-Kubik K; Graczyk-Pol E; Witkowska A; Marosz-Rudnicka A; Nestorowicz K; Dziopa J; Szlendak U; Warzocha K; Lange A;
    Biol Blood Marrow Transplant; 2015 May; 21(5):829-39. PubMed ID: 25617806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease.
    Dunbar EM; Buzzeo MP; Levine JB; Schold JD; Meier-Kriesche HU; Reddy V
    Haematologica; 2008 Dec; 93(12):1852-8. PubMed ID: 18945751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
    Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia: A Japanese National Registry Study.
    Arima N; Nakamura F; Yabe T; Tanaka J; Fuji S; Ohashi K; Fukuda T; Miyamura K; Iwato K; Eto T; Mori T; Kobayashi N; Hoshino T; Kato C; Kanamori H; Nakamae H; Atsuta Y; Morishima Y; Kanda Y
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):423-31. PubMed ID: 26456260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK cell maturation to CD56(dim) subset associated with high levels of NCRs overrides the inhibitory effect of NKG2A and recovers impaired NK cell cytolytic potential after allogeneic hematopoietic stem cell transplantation.
    Ghasemzadeh M; Hosseini E; Schwarer AP; Pourfathollah AA
    Leuk Res; 2016 Apr; 43():58-65. PubMed ID: 26856773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome.
    Kim HT; Armand P; Frederick D; Andler E; Cutler C; Koreth J; Alyea EP; Antin JH; Soiffer RJ; Ritz J; Ho VT
    Biol Blood Marrow Transplant; 2015 May; 21(5):873-80. PubMed ID: 25623931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reconstitution of lymphocyte subpopulations after hematopoietic stem cell transplantation: comparison of hematologic malignancies and donor types in event-free patients.
    Park BG; Park CJ; Jang S; Chi HS; Kim DY; Lee JH; Lee JH; Lee KH
    Leuk Res; 2015 Dec; 39(12):1334-41. PubMed ID: 26422556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Relapse-Free Survival in Patients With High Natural Killer Cell Doses in Grafts and During Early Immune Reconstitution After Allogeneic Stem Cell Transplantation.
    Minculescu L; Fischer-Nielsen A; Haastrup E; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Sengelov H; Marquart HV
    Front Immunol; 2020; 11():1068. PubMed ID: 32547559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel method to quantify and characterize leukemia-reactive natural killer cells in patients undergoing allogeneic hematopoietic stem cell transplantation following conventional or reduced-dose conditioning.
    Penack O; Fischer L; Stroux A; Gentilini C; Nogai A; Muessig A; Ganepola S; Lange T; Kliem C; Marinets O; Blau IW; Thiel E; Uhareka L
    Int J Hematol; 2007 May; 85(4):326-32. PubMed ID: 17483077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation.
    Clausen J; Wolf D; Petzer AL; Gunsilius E; Schumacher P; Kircher B; Gastl G; Nachbaur D
    Clin Exp Immunol; 2007 Jun; 148(3):520-8. PubMed ID: 17493020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients.
    Bhatt ST; Bednarski JJ; Berg J; Trinkaus K; Murray L; Hayashi R; Schulz G; Hente M; Grimley M; Chan KW; Kamani N; Jacobsohn D; Nieder M; Hale G; Yu L; Adams R; Dalal J; Pulsipher MA; Haut P; Chaudhury S; Davis J; Jaroscak J; Andreansky M; Willert J; Shenoy S
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):556-561. PubMed ID: 30321596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
    Zhou H; Bao X; Wu X; Tang X; Wang M; Wu D; He J
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of HLA-E polymorphisms on relapse following allogeneic hematopoietic stem cell transplantation.
    Hosseini E; Schwarer AP; Jalali A; Ghasemzadeh M
    Leuk Res; 2013 May; 37(5):516-9. PubMed ID: 23395341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors.
    Remberger M; Ringdén O; Hägglund H; Svahn BM; Ljungman P; Uhlin M; Mattsson J
    Clin Transplant; 2013; 27(4):E368-74. PubMed ID: 23701240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease post-transplant relapse using donor-derived expanded NK-cells.
    Ciurea SO; Kongtim P; Soebbing D; Trikha P; Behbehani G; Rondon G; Olson A; Bashir Q; Gulbis AM; Indreshpal K; Rezvani K; Shpall EJ; Bassett R; Cao K; Martin AS; Devine S; Horowitz M; Pasquini M; Lee DA; Champlin RE
    Leukemia; 2022 Jan; 36(1):155-164. PubMed ID: 34312462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of very early CD4(+) /CD8(+) T cell counts on the occurrence of acute graft-versus-host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation.
    Huttunen P; Taskinen M; Siitonen S; Saarinen-Pihkala UM
    Pediatr Blood Cancer; 2015 Mar; 62(3):522-8. PubMed ID: 25417898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.